header image

Poster Presentation

Poster Blasts

March 21st 2023

Poster Blasts

March 22nd 2023

Cancer immunotherapies

ID

Title

Author

3 Additional Immunovirotherapy of NUT Carcinoma with the Oncolytic Herpes Simplex Virus T-VEC and the Immune Checkpoint Inhibitor Pembrolizumab Linus Kloker
4 A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy Mary Elisabeth Carter
6 Acidosis promotes immune escape through the IFN-γ-induced induction of PD-L1 transcription in cancer cells Dimitri Stowbur
13 NFAT2 regulates susceptibility of chronic lymphocytic leukemia cells to perforin-mediated killing Melanie Märklin
15 CAR T-cell metabolomics reveals dynamic adaptions and distinct metabolic phenotypes upon antigen stimulation Laimdota Zizmare
17 timsTOF mass spectrometry-based immunopeptidomics refines tumor antigen identification Naomi Hoenisch Gravel
22 DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition Jens Bauer
24 Target cell-restricted CD28 bispecific antibodies that sustain antitumor activity of CD3-bispecific antibodies Latifa Zekri
29 Preliminary results of a Phase I trial of personalized multi-peptide vaccines combined with the TLR1/2 ligand XS15 under Bruton-Tyrosine-Kinase inhibitor (BTKi) treatment in CLL patients Yacine Maringer
30 Immunopeptidomics of small cell lung cancer Anna Schöllhorn
34 Strong immune response to EO2401, a microbiome-derived therapeutic vaccine + nivolumab, in recurrent glioblastoma – The EOGBM1-18/ROSALIE study Ana Maia dos Santos Leite
37 Role of prophylactic cranial irradiation in small cell lung cancer and neuroendocrine carcinomas in the era of immune-checkpoint therapy Jerome-Maurice Dobrowolski
38 Evaluation of immune checkpoint antigens and stem cell markers on early versus late passage organoids from urothelial carcinoma cells Simon Walz
43 Making the effect visible – Nanobodies for in vivo imaging of activated T cells Desiree I. Frecot
44 Two birds with one stone: SIRPα nanobodies to visualize and modulate the myeloid cell population Teresa R. Wagner
44 Two birds with one stone: SIRPα nanobodies to visualize and modulate the myeloid cell population Simone Blaeß
57 Deciphering organ-specific immunoresistance in breast cancer metastasis using multiscale microscopy Gina Dunkel
62 Combined T cell and immune checkpoint inhibitor-based immunotherapy induces strong anti-tumoral T cell responses in a mouse model of progressed insular cell carcinomas Barbara Schörg
63 Priming Solid Cancers to Heat up and Boost (CAR) T Cell Effector Function Moustafa Moustafa-Oglou
71 Analysis of neoantigen distribution, presentation and recognition by patient‑individualized vaccine-induced specific T cells in children with relapsed acute lymphoblastic leukaemia (ALL) Germano Amorelli
76 AdCAR-T Tuning to Overcome Immune Escape in Pediatric AML Anna-Sophia Mast
78 Role of prophylactic cranial irradiation in small cell lung cancer and neuroendocrine carcinomas in the era of immune-checkpoint therapy Jerome-Maurice Dobrowolski
81 Longitudinal PET-monitoring of immunotherapy response by visualization of T cell activation kinetics within the tumor microenvironment Simone Blaeß
82 The microbiome as a checkpoint blockade therapy adjuvant Lukas Mager
92 Prospective phase I/II trial of an individualized peptide vaccine in pediatric and AYA patients with metastasized fusion-driven sarcomas following standard treatment – PerVision Christian M. Seitz
95 Modulated signaling in BE-CAR(E) T cells enhances antitumor efficacy Philip Bucher
107 Ex vivo generation of cytotoxic CD4 T cells to target solid and hematological cancer Anna Ohmayer
110 High frequencies of peripheral Vδ1 T cells are associated with poor overall survival of melanoma patients undergoing PD-1 blockade and a late-differentiated phenotype Nicola Herold
113 Sublethal T cell hits induce melanoma cell senescence during immuno-thermal therapy Oliver Hihn
120 The triplebody SPM-2 (CD123-16-33) efficiently lyses MOLM-13 and pediatric AML blasts in combination with NK cells Florian Heubach
125 Pan-B Cell Targeting by Adapter CAR T Cells (AdCAR-T) Prevents Antigen Escape in B-phenotypic malignancies Simon Krost
133 Loss of TP53 in gastric cancer activates a pro-inflammatory program resulting in novel vulnerabilities for immune cell-based therapeutic approaches Martina Rausch
136 Small Molecule Inhibitors of p38a improve function and prevent exhaustion of CAR T-cells in Cancer Immunotherapies Maximilian Feige
139 Multiplex Targeting by Adapter CAR T Cells (AdCAR-T) to Cope with Inter- and Intratumoral Heterogeneity in Acute Myeloid Leukemia Daniel Atar
23 Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies Latifa Zekri
134 CRISPR screens in primary CD8+ T-cells identify Kdm2b and Roquin-1 as modulators of T-cell fitness and anti-tumor immunity Markus Schäfer

Entry level researcher

ID

Title

Author

69 Mechanistic dissection of the role of Tbx3 and Prdm5 in lineage determination of Primary Liver Cancer Aram Rahmani Pour
86 Understanding and targeting immunometabolism to improve therapeutic efficacy of CAR T cells Nadine Brückner
90 Combinatorial targeting with (senolytic) CAR therapy Meike Thiemann
97 Targeting cancer driver mutations with engineered T cells Mara Mitstorfer
98 CAR NK cells in the context of senescent tumor cells Karlotta Bartels
101 Reciprocal interaction between senescent tumor cells and CAR T cells Steffen Hardy
104 Development and Validation of a Novel Liquid Chromatography-Mass Spectrometry Methodology for GMP-conform Quality Control of Peptide Vaccine Cocktails in Individualized Immunotherapy Setting Melek Tutku Özbek
124 Role for Girdin and Daple in melanoma progression and therapy resistance Ana Villar
137 Boosting ORFV vector vaccine efficacy by triggering innate immune signaling and optimizing antigen expression of antigen presenting cells Matthias Helmold
138 Improving the efficacy of parapoxvirus vector-based tumor vaccines Verena Haug
142 Determining the dynamics of immunity to influenza vaccination in cancer patients using multi-omics and repertoire profiling tools Carlotta Schieler
146 Distinct genetic ablations increase memory formation in CD19 CAR T cells Lukas Schönauer

Functional and molecular multiparametric imaging of cancer

ID

Title

Author

9 Deuterium Metabolic Imaging – Rediscovery of a Powerful Imaging Tool to Study In Vivo Metabolism Laura Kuebler
10 Systematic Side-by-Side Comparison of [18F]Olaparib and [18F]Talazoparib as PARP Imaging Agents in an HR-Deficient Breast Cancer Xenograft Model Sophie Stotz
26 Establishing Fluorescence Lifetime Imaging Microscopy to determine responsiveness of Patient Derived Microtumors to different cancer therapies Sally Williamson
27 Marker-free identification of immune cells in the tumor microenvironment Julia Alber
41 MRI for tissue classification of subcutaneus colon cancer using oxygen enhanced, dynamic contrast enhancement (DCE) MRI and [18F]FAZA PET Marta Vuozzo
45 Clinical application of [18F]FPyGal: the detection of in vivo senescence Jonathan Cotton
46 In vivo evaluation of [18F]Fluoroethyl Fucose: a PET tracer for imaging and studying tumor senescence Jonathan Cotton
47 Evaluation of a New Senescence Tracer Generation based on FPyGal Francisco José Reche Pérez
64 Image guided multimodal investigations of human breast cancer tissue correlate [18F]-FDG tracer uptake with oxidative stress patterns and decipher distinct metabolic phenotypes in tumor center and periphery depending on hormone receptor and HER2 status Christoph Trautwein
66 Label-free imaging for in situ drug efficacy testing on patient-derived cancer organoids Julia Marzi
72 Immunological Profiling of Cancer by automated Ultra-High Content Imaging Sophia Scheuermann
75 S3-CIMA: Supervised spatial single-cell image analysis for the identification of disease-associated cell type compositions in tissue Sepideh Babaei
83 Non-invasive detection of extracellular lactosis and acidosis by shift/acido CEST MRI Anaïs Choffart
84 Impact of the metabolic interplay between immune cells and cancer cells during immunotherapy response: a multimodal imaging study Sixing Li
94 [89Zr]Zr-DFO-durvalumab PET/CT to predict responses to neo-adjuvant durvalumab in early-stage non-small cell lung cancer Evelien Van Genugten
119 [18F]AlF-RESCA-GSA a potential radiotracer for non-invasive staging hepatocellular carcinomas Kimia Samadikhah

Functional target discovery, preclinical models and new drugs in oncology

ID

Title

Author

8 Generation and characterization of novel mouse models for OAT2 and OAT7 located in the sinusoidal membrane of hepatocytes Anne Nies
11 Understanding and exploiting treatment-induced vulnerabilities in experimental glioma for novel combination therapies: Argyrin F plus PD-1 blockade Bianca Walter
19 A preclinical assay system comprised of patient derived microtumors combined with protein profiling and immunophenotyping for assessment of individualized treatment responses Christian Schmees
20 Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients Gyuntae Bae
25 Characterization of the exome, transcriptome, and immunopeptidome to map alterations in newly diagnosed and recurrent glioblastoma Marissa L. Dubbelaar
39 Prior neoadjuvant chemotherapy correlates with reduced culture e6ciency in patient derived bladder cancer organoids Simon Walz
42 Functional characterization of therapy response to Somatostatin Receptor Analogs in a novel in vitro model of pancreatic neuroendocrine neoplasms Katharina Gries
49 1st in class small molecule inhibitors of MKK4 to overcome resistance towards KRASG12C or MEK inhibitors in Non-small cell lung cancer Moritz Schmidt
51 Development and characterization of kinase sparing TPX2-tethering Aurora Kinase A ligands for the therapy of cancer Athina Anastasia Moschopoulou
55 Exploiting LXRalpha activation for lipotoxic cancer therapies Pascal Wölffing
56 An optimized system for genome-scale CRISPR screens identifies in vivo dependencies in pancreatic cancer Vivien Vogt
60 Development and Evaluation of B7-H3 (CD276) targeted Adapter Molecules for Theranostic Application in the Context of the AdapterCAR (AdCAR) Platform Beate Kristmann
67 A novel CRISPR/Cas9 knockout library uncovers pan-essential miRNAs in human cancer cell lines Daniel J. Merk
68 Co-transcriptional splicing is a vulnerability of Ras-driven cells Verena Wagner
70 In vivo RNAi screen identifies TNMD as a Tumor Suppressor Gene in Liver Cancer Aram Rahmani Pour
74 Generation of TCR-transgenic virus-specific T cells by lentiviral transduction as a source for use in research and clinics Anne-Marie Arendt
77 SMARCC1 controls oncogenic NOTCH1 signaling in T-cell acute lymphoblastic leukemia Khalid Shoumariyeh
79 A Sentinel Lymph Node procedure in early-stage lung cancer: ex-vivo exploration and first clinical results Desi ter Woerds
80 The p110 alpha isoform in the PI3K pathway as a promising target for targeted therapy for BRAF mutant malignant melanoma Heike Niessner
85 Inflammasome in a cage: NLRP3 forms oligomeric 'cages' to mediate NLRP3 activation Liudmila Andreeva
89 Effects of targeted YAP/TAZ-TEAD inhibition on mesothelioma Hanne Hillen
91 Discovering novel therapeutic targets for drug-induced senescence in liver cancer Ana Tapia-Abellan
96 Development and Characterization of the First-in-Class Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) inhibitor Ricardo Serafim
102 Design and synthesis of novel fluorescently labeled analogs of Vemurafenib, targeting MKK4 Leon Katzengruber
105 Identifying biomarkers for selinexor response in HCC Vanessa Hollfoth
106 Novel AurkA ligands as therapy option for p53-altered carcinoma Juliander Reiner
108 Targeting the R-Spine: Design, Synthesis and Biological Evaluation of Novel Type I½ p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency and Prolonged Target Residence Time: A Promising Treatment Option for Colorectal Cancer Frederik Hacker
109 Development of a high-throughput system for advanced functional cell analysis for 2D and 3D cell ensembles Sonja Stoelzle-Feix
111 Don't you know that you're lipotoxic? Structural determinants of LXR-mediated lipotoxicity Júlia Galvez Bulhões Pedreira
112 Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivity Michael Forster
114 From off-to on-target: New BRAF inhibitor template derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4) Valentin Wydra
115 Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors Masanja Trautz
117 Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) Pascal Sander
121 Running in harmony: HUWE1 coordinates RNAPII-dependent ATM signaling at collisions with replication forks Elias Einig
127 Don't you know that you're lipotoxicity? Structural determinants of LXR-mediated lipotoxicity Júlia Galvez Bulhões Pedreira
129 Overexpression of Oncogenic Inhibitory-ASPP (apoptosis stimulating protein of p53) Results in Therapy Resistance and Adverse Outcome in AML Mihada Bajrami Saipi
130 Harnessing Endogenous ADAR for Therapy Hakariya Hayase
135 Short term Antibiotics Treatment increases Liver Tumorigenesis via induction of Long Term Dysbiosis Svenja Schütte
141 Sorafenib drives mitophagy across hepatocellular cell boundaries through tunneling nanotubes Ana Luiza Diogo de Oliveira
147 Modeling Leukemia Development in context of Congenital Neutropenia Haaf Jeremy

Other topics

ID

Title

Author

2 PARP inhibitors effectively reduce melanoma cell growth and synergize with MAPK inhibitors through a synthetic lethal interaction in vitro and in vivo Lisa Marie Fröhlich
7 PET Imaging of Senescence in a Pulmonary Fibrosis Mouse Model Nicolas Bézière
12 NFAT1 and NFAT2 are major regulators in NK cell immunosurveillance Melanie Märklin
32 Phase I/II trial of a peptide-based COVID-19 vaccine to induce SARS‑CoV-2-specific T cell responses in cancer patients with B cell deficiency Annika Nelde
36 Genetic-profiling in a real-life cohort of sarcoma patients  for identifying potential therapeutic targets Branko Calukovic
52 MYC determines lineage commitment in primary liver tumorigenesis Luana D'Artista
59 Iron accumulation drives fibrogenesis, senescence, and the senescence-associated secretory phenotype Mate Maus
61 Imaging immune cell activation in non-alcoholic steatohepatitis by in vivo PET/MRI using the radiotracer [18F]FAC Vera Jörke
65 Explainable diagnosis by leveraging human-interpretable features through mutual information minimization Erick Cobos
73 Stratification of ovarian cancer borderline from high-grade serous carcinoma patients via blood serum NMR spectroscopy of metabolites, lipoproteins and inflammatory markers Georgy Berezhnoy
88 Diffusion phantom with tissue-like MR properties relevant to the application of DW-MRI in cancer Victor Fritz
103 Establishment of an innovate closed vector production platform Florian Schinle
122 Experimental Treatment with ATR Inhibitors (ATRi): Challenges in Trial Recruitment Mihada Bajrami Saipi
131 Cytomegalovirus-specific antibody titers associate with a late stage differentiated T cell signature and predict poorer survival in melanoma patients under anti-PD-1 blockade Kilian Wistuba-Hamprecht
132 The dimeric deubiquitinase Usp28 integrates 53bp1 and Myc functions to limit DNA damage Chao Jin
143 1st in Class Small Molecule Inhibitors of MKK4 for the Treatment of Acute and Chronic Liver Diseases Stefan Zwirner
148 Generation of enhanced artificial miRNAs for RNAi-based therapeutics Giuseppe Militello